Diablo is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Second Mitochondria-Derived Activator of Caspases (SMAC) | |
|---|---|
| Gene Symbol | DIABLO |
| Full Name | Direct IAP-Binding Protein with Low pI |
| Chromosome | 12q24.31 |
| NCBI Gene ID | 56616 |
| OMIM | 604476 |
| Ensembl ID | ENSG00000140297 |
| UniProt ID | Q9NR28 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Cancer |
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
DIABLO (also known as SMAC - Second Mitochondria-Derived Activator of Caspases) is a mitochondrial protein released into the cytosol during apoptosis. Its primary function is to promote caspase activation by neutralizing Inhibitor of Apoptosis Proteins (IAPs). SMAC/DIABLO binds to IAPs (including XIAP, cIAP1, cIAP2) through its N-terminal tetrapeptide motif, displacing caspases from IAP inhibition.
Upon mitochondrial outer membrane permeabilization (MOMP), SMAC/DIABLO is released from the mitochondrial intermembrane space into the cytosol, where it binds to and neutralizes IAP proteins. This removes the brake on caspase activation and promotes efficient execution of apoptosis. SMAC/DIABLO acts in parallel with cytochrome c release, providing a caspase-activating signal.
SMAC/DIABLO is expressed in most tissues, with high expression in testis, heart, and brain. Like other mitochondrial intermembrane space proteins, it is synthesized with an N-terminal targeting sequence that directs it to mitochondria.
| Disease | Variants | Inheritance | Mechanism |
|---|---|---|---|
| Alzheimer's Disease | Altered release | Acquired | Promotes caspase activation in neurons |
| Parkinson's Disease | Altered release | Acquired | Contributes to dopaminergic neuron death |
| Cancer | Often downregulated | Somatic | Loss promotes tumor survival |
The study of Diablo has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.